<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112459203</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112459203</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Estimation of <italic>BDNF</italic> gene polymorphism and predisposition to dependence development for selected psychoactive compounds</article-title>
<subtitle>Genetic aspects of addiction with the selected drugs, amphetamine, tetrahydrocannabinol and opiates</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Biskupska</surname>
<given-names>J</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112459203">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Borowiak</surname>
<given-names>KS</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112459203">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327112459203"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karlin-Grażewicz</surname>
<given-names>K</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112459203">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Janus</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112459203">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Waloszczyk</surname>
<given-names>P</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112459203">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Potocka-Banaś</surname>
<given-names>B</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112459203">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Machoy-Mokrzyńska</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327112459203">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ossowski</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112459203">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ciechanowicz</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112459203">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0960327112459203">
<label>1</label>Division of Clinical Toxicology and Pathobiochemistry, Department of Forensic Medicine, Pomeranian University of Medicine, Szczecin, Poland</aff>
<aff id="aff2-0960327112459203">
<label>2</label>Department Clinical and Molecular Biochemistry, Pomeranian University of Medicine, Szczecin, Poland</aff>
<aff id="aff3-0960327112459203">
<label>3</label>Chair and Department of Pharmacology, Pomeranian University of Medicine, Szczecin, Poland</aff>
<author-notes>
<corresp id="corresp1-0960327112459203">Krzysztof S Borowiak, Division of Clinical Toxicology and Pathobiochemistry, Department of Forensic Medicine, Pomeranian University of Medicine, Powstańców Wlkp. 72, Szczecin 70-111, Poland. Email: <email>boroks@sci.pam.szczecin.pl</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>236</fpage>
<lpage>240</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The etiology of drug addiction, a central nervous system (CNS) disease, is not fully known. This complex problem is believed to be connected with concurrently affecting genetic, psychological and environmental factors. The development of addiction is connected with CNS reinforcement system and dopaminergic neurotransmission. Molecular processes are postulated to be of universal character and allow to presume a similar mechanism of dependence for both ethanol and other substances. Therefore, elements of dopaminergic transmission become excellent candidates for the examination of genetic influence on the development of addiction. A relationship between alcoholic disease and the presence of <italic>TaqIA1</italic> and <italic>DRD2</italic> alleles permits to initiate another investigation of gene-coding DRD2 dopamine receptor. The latest results indicate the importance of brain-derived neurotrophic factor (BDNF) in the regulation of dopaminergic route. The purpose of this research was to reveal the relationship between the <italic>Val66Met</italic> <italic>BDNF</italic> gene polymorphism and dependence of psychoactive agent. The examinations were performed with the Local Research Ethics Committee approval and patient’s consent. The study group consisted of 100 patients (88 men and 12 women) aged 18–52 years, qualified for research program according to the International Classification of Diseases, Tenth Revision (ICD-10) requirements, medical examination and detailed questionnaire.</p>
</abstract>
<kwd-group>
<kwd>THC</kwd>
<kwd>amphetamine</kwd>
<kwd>opiates</kwd>
<kwd>addiction</kwd>
<kwd>brain-derived neurotrophic factor polymorphism</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112459203">
<title>Introduction</title>
<p>Drug addiction is known to be a chronic and reversible disease of central nervous system (CNS), based on the yet not fully investigated substructure, which is of interest to clinicians, scientist and lawyers. This phenomenon is thought to be influenced by several concurrent parameters (environmental and psychological), one of them being closely connected with genetic factors. Genetic polymorphism may influence the risk of dependence evolution and frequency of intake of drug abuse substances, whereas environmental agents are responsible for occasional contact.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112459203">1</xref>
</sup> The genetic predisposition may be responsible for 50–60% risk of ethanol dependence.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112459203">2</xref>
</sup> The universal mechanism of dependence extension was postulated to be common for both ethanol and other psychoactive compounds through dopaminergic transmission. Therefore, the polymorphism of dopaminergic neurotransmission genes (<italic>DRD2</italic>) and brain-derived neurotrophic factor (BDNF) becomes the adequate candidates for the examination of correlation between genetic factors and evolution of addiction.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112459203">3</xref>
</sup>
</p>
<p>The recent associative examinations of the human genome have revealed the relationship between the locus of coding <italic>BDNF</italic> gene polymorphism and the dependence of psychoactive agents.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112459203">4</xref>
</sup> It was proved that the expression of <italic>BDNF</italic> gene in CNS changed after exposure to alcohol, nicotine, cocaine or amphetamine, and similarly during the period of abstinence.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112459203">5</xref>
</sup> The BDNF coding gene is located in the chromosome 11p13-15 region. The polymorphism of G196A gene is connected with substitution of guanine with adenine in the position 196 of the coded sequence. It results in the substitution of valine amino acid with methionine at the protein synthesis level.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112459203">6</xref>,<xref ref-type="bibr" rid="bibr7-0960327112459203">7</xref>
</sup> The obtained observations are ambiguous, although some of the examination results confirm this association.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112459203">7</xref>
<xref ref-type="bibr" rid="bibr8-0960327112459203"/>
<xref ref-type="bibr" rid="bibr9-0960327112459203"/>–<xref ref-type="bibr" rid="bibr10-0960327112459203">10</xref>
</sup>
</p>
<sec id="section2-0960327112459203">
<title>Aim of the research</title>
<p>The aim of the study was to examine the association between <italic>G196A BDNF</italic> gene polymorphism and predisposition to the dependence development for selected psychoactive compounds (amphetamines, tetrahydrocannabinol (THC) and opiates) in patients from Dependence Treatment Centre in Szczecin, Poland.</p>
</sec>
</sec>
<sec id="section3-0960327112459203" sec-type="methods">
<title>Methods</title>
<p>The examinations were performed with the Local Research Ethics Committee approval and consent was obtained from each patient. The group under investigation consisted of 100 patients (88 men and 12 women) at the age of 18–52 years, from Szczecin Centre of Dependence Treatment. The dependence status (simple or multidrug) was established according to the International Classification of Diseases, Tenth Revision (ICD-10) requirements. Patients were qualified for research program according to the ICD-10 requirements, medical examination and detailed questionnaire.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112459203">3</xref>
</sup>
</p>
<p>The blood was collected on a sterile piece of cotton and extracted for DNA isolation. Then genomic DNA was extracted from the dried stain. It was performed with universal kit Sherlock AX (A&amp;A Biotechnology for Biological Traces Examination, Gdansk, Poland). The control DNA samples were obtained from umbilical cord blood from 114 infants (95 males and 19 females), born during the years 2004 and –2005 at the Gynecology and Obstetrics Department.</p>
<p>Estimation of <italic>Val66Met BDNF</italic> gene polymorphism was carried out with polymerase chain reaction (PCR; restriction fragment length polymorphism) technique (<xref ref-type="fig" rid="fig1-0960327112459203">Figure 1</xref>). The pairs of oligonucleotides: 5′ – TGT CTG GTG CAG CTG GAG – 3′ as a sense primer and 5′ – TCG GCG GGC AGG GTC AGA G – 3′ as a nonsense primer were used.<sup>
<xref ref-type="bibr" rid="bibr11-0960327112459203">11</xref>
</sup> DNA samples (40 ng) were amplified in the 20 µl solution including 4 pM each starter kits, 2.5 mM each triphosphates (dATP, dTTP, dCTP and dGTP), PCR buffer (1.5 mM MgCl<sub>2</sub> concentration) and 0.5 unit of Taq polymerase (MBI Fermentas). Amplification was performed with termocycler-Mastercycler gradient (Eppendorf) under the following conditions: initial denaturation at 94°C for 5 min, and next 35 cycles, denaturation at 94°C for 20s, starter binding for 40s at 62°C and chain elongation at 72°C for 40s. The PCR process ended with 8-min chain elongation at 72°C. Subsequently, all the PCR amplicons were digested by restricted enzyme, and electrophoresis separation (3% agar gel colored with ethidium bromide) was performed. The electrophoresis files were documented with UV camera DS-34 (Polaroid system).</p>
<fig id="fig1-0960327112459203" position="float">
<label>Figure 1.</label>
<caption>
<p>Polymorphism of <italic>Val66Met</italic> <italic>BDNF</italic> gene. PCR products after digestion by restrictive enzyme Eco 72I (MBI Fermentas). MW: size marker; 1: non-digested PCR product; 2: heterozygote AG; 3: homozygote GG; 4: homozygote AA. BDNF: brain-derived neurotrophic factor; PCR: polymerase chain reaction.</p>
</caption>
<graphic xlink:href="10.1177_0960327112459203-fig1.tif"/>
</fig>
<p>The 576 base pairs length was a PCR product for used primer pairs. The allele of ‘wild’ G type is digested by Eco72I restricted enzyme result in DNA fragments of the length 336 and 210 base pairs. A loss of restriction position in the mutated allele A resulted in non-digestion process.</p>
<sec id="section4-0960327112459203">
<title>Statistical analysis</title>
<p>The frequency of respective genotypes was estimated with Chi-quadrat test. Qualitative variables were estimated with Chi-quadrat test (frequency of examined genotypes), while quantitative variables with the Mann–Whitney <italic>U</italic> test. The results with <italic>p</italic> &lt; 0.05 were accepted as statistically significant.</p>
</sec>
</sec>
<sec id="section5-0960327112459203">
<title>Results</title>
<p>In the present article, no differences for examined genes and alleles disposition as well as for studied and control groups were observed (<italic>p</italic> &gt; 0.05; <xref ref-type="table" rid="table1-0960327112459203">Table 1</xref>).</p>
<table-wrap id="table1-0960327112459203" position="float">
<label>Table 1.</label>
<caption>
<p>Distribution of genotype and allele polymorphism of <italic>Val66Met BDNF</italic> gene in the studied and control groups.</p>
</caption>
<graphic alternate-form-of="table1-0960327112459203" xlink:href="10.1177_0960327112459203-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">BDNF</th>
<th colspan="3">Genotypes</th>
<th rowspan="2">X<sup>2</sup>
</th>
<th rowspan="2">
<italic>p</italic> Value</th>
<th colspan="2">Alleles</th>
<th rowspan="2">χ<sup>2</sup>
</th>
<th rowspan="2">
<italic>p</italic> Value</th>
</tr>
<tr>
<th>AA (%)</th>
<th>AG (%)</th>
<th>GG (%)</th>
<th>A</th>
<th>G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studied group, <italic>n</italic> = 100</td>
<td>2 (2)</td>
<td>28 (28)</td>
<td>70 (70)</td>
<td rowspan="2">0.10</td>
<td rowspan="2">0.95</td>
<td>32</td>
<td>168</td>
<td rowspan="2">0.004</td>
<td rowspan="2">0.95</td>
</tr>
<tr>
<td>Control group, <italic>n</italic> = 114</td>
<td>3 (2.6)</td>
<td>31 (27.2)</td>
<td>80 (70.2)</td>
<td>37</td>
<td>191</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112459203">
<p>BDNF: brain-derived neurotrophic factor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the study group, no statistically significant differences for most of the estimated parameters (<xref ref-type="table" rid="table2-0960327112459203">Table 2</xref>) were noted for both homozygotes (GG) and patients with mutated allele A (AG and AA). The only statistically significant differences were found to be the duration of intake and the attempts of abstinence.</p>
<table-wrap id="table2-0960327112459203" position="float">
<label>Table 2.</label>
<caption>
<p>Studied group characteristics in relationship to genotype <italic>BDNF</italic> gene.<sup><xref ref-type="table-fn" rid="table-fn3-0960327112459203">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table2-0960327112459203" xlink:href="10.1177_0960327112459203-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>AG and AA<sup><xref ref-type="table-fn" rid="table-fn4-0960327112459203">b</xref></sup>, <italic>n</italic> = 30</th>
<th>GG, <italic>n</italic> = 70</th>
<th>
<italic>p </italic>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F/M)</td>
<td>2/28</td>
<td>10/60</td>
<td>NS</td>
</tr>
<tr>
<td>Age (years)</td>
<td>27.1 ± 7.6</td>
<td>25.3 ± 5.6</td>
<td>NS</td>
</tr>
<tr>
<td>Initiation age (years)</td>
<td>16.5 ± 3.9</td>
<td>17.4 ± 3.5</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of intake (months)</td>
<td>9 ± 5.6</td>
<td>7.1 ± 4.13</td>
<td>
<italic>p</italic> = 0.04</td>
</tr>
<tr>
<td>Abstinence (y/n)</td>
<td>22/8</td>
<td>34/36</td>
<td>p = 0.02</td>
</tr>
<tr>
<td>Period of abstinence</td>
<td>0.9 ± 1.3</td>
<td>0.7 ± 1.009</td>
<td>NS</td>
</tr>
<tr>
<td>Politoxicomania</td>
<td>16/14</td>
<td>42/28</td>
<td>NS</td>
</tr>
<tr>
<td>Alcohol (y/n)</td>
<td>14/16</td>
<td>24/46</td>
<td>NS</td>
</tr>
<tr>
<td>Nicotine (y/n)</td>
<td>25/5</td>
<td>63/7</td>
<td>NS</td>
</tr>
<tr>
<td>Mental disorders (y/n)</td>
<td>8/22</td>
<td>13/57</td>
<td>NS</td>
</tr>
<tr>
<td>Detoxification unit (y/n)</td>
<td>16/14</td>
<td>31/39</td>
<td>NS</td>
</tr>
<tr>
<td>Therapeutic center (y/n)</td>
<td>14/16</td>
<td>30/40</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0960327112459203">
<p>NS: nonsignificant; BDNF: brain-derived neurotrophic factor.</p>
</fn>
<fn id="table-fn3-0960327112459203">
<p>
<sup>a</sup>The quantitative data are shown as a mean ± SD.</p>
</fn>
<fn id="table-fn4-0960327112459203">
<p>
<sup>b</sup>The genotypes AA and mutated A allele were calculated jointly (higher quantity) to use statistical tests.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The obtained distribution of genotypes was not significantly different compared with prospective schedule based on Hardy–Weinberg equation (<italic>p</italic> = 0.8).</p>
</sec>
<sec id="section6-0960327112459203">
<title>Discussion</title>
<p>The hitherto examinations of <italic>G196A BDNF</italic> gene polymorphism and correlation with the development of dependence were performed exclusively for Asian populations and the obtained results were ambiguous. Results obtained by Itoh et al. indicated lack of such an association among Japanese metamphetamine addicts.<sup>
<xref ref-type="bibr" rid="bibr12-0960327112459203">12</xref>
</sup> Similarly, the studies of Cheng et al. did not prove correlation for polymorphism G196A variants for Euro-American patients addicted to drugs and alcohol. However, they observed significantly higher frequency of <italic>712G</italic> alleles and 712G/712G genotype (single nucleotide polymorphism) in patients with dependence syndrome.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112459203">8</xref>
</sup>
</p>
<p>The observations of Matsushita et al. may indicate that the polymorphism of <italic>G196A BDNF</italic> gene results in the modification of alcohol disease clinical course (higher frequency of A allele in alcoholic patients with pathological disorders as a violence predisposition and delirium episodes) rather than in a higher susceptibility to dependence development.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112459203">7</xref>
</sup>
</p>
<p>On the other hand, Cheng et al. confirmed the association of BDNF polymorphism and susceptibility of addiction as well as younger age of initiation in China’s metamphetamine and heroin users.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112459203">8</xref>
</sup> Gratacós et al. used the meta-analysis method for the estimation of previously performed ‘case control’ studies and confirmed the polymorphism of <italic>G196A BDNF</italic> gene connection with addictions, feeding disorders and schizophrenia.<sup>
<xref ref-type="bibr" rid="bibr10-0960327112459203">10</xref>
</sup>
</p>
<p>In the present study, no statistically significant connection with the polymorphism of <italic>G196A BDNF</italic> gene and dependence status of 100 examined patients (amphetamine, THC and opiates) was observed. However, results of our investigation may indicate that the mutation of <italic>BDNF</italic> gene (GG genotype, allele A) can result in the clinical course of addiction (duration of addiction and frequency of abstinence). These observations would support the previously mentioned observations by Matsushita et al. for alcohol disease.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112459203">7</xref>
</sup> The methodology and technical problems, connected with molecular examination of addiction, were previously described and could explain differences and contradictory results obtained by researchers. One should remember that psychological disorders as well as dependences are oligo-gene qualified, and therefore they are not inherited according to Mendel’s laws.</p>
<p>A number of genes were identified as responsible for the development of dependence, but none of them is indispensable and sufficient to initiate the disorders; however, all of them may affect addiction.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112459203">8</xref>
<xref ref-type="bibr" rid="bibr9-0960327112459203"/>–<xref ref-type="bibr" rid="bibr10-0960327112459203">10</xref>
</sup> The differences of susceptibility within a population result from individual genetic differences, environmental factors and their mutual interactions.</p>
<p>There is evidence that social and environmental elements (e.g. availability of drugs of abuse) influence the age of initiation and, above all, sustaining an addiction process.<sup>
<xref ref-type="bibr" rid="bibr12-0960327112459203">12</xref>,<xref ref-type="bibr" rid="bibr13-0960327112459203">13</xref>
</sup>
</p>
<p>Most of divergences in earlier results can be explained by a high heterogeneity of the studied population, stratification effect, clinical course of disorders and different clinical and diagnostic criteria for studied and control groups.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112459203">14</xref>,<xref ref-type="bibr" rid="bibr15-0960327112459203">15</xref>
</sup> Therefore, the umbilical infant blood from the same population was used as a control group in the present study to limit the influence of environmental, social and psychological factors on the genetic examinations. This kind of control material was previously successfully applied and described by other researchers.<sup>
<xref ref-type="bibr" rid="bibr11-0960327112459203">11</xref>,<xref ref-type="bibr" rid="bibr16-0960327112459203">16</xref>,<xref ref-type="bibr" rid="bibr17-0960327112459203">17</xref>
</sup> However, it is understood that it could not potentially eliminate the later mutations.</p>
</sec>
<sec id="section7-0960327112459203">
<title>Conclusions</title>
<list list-type="order">
<list-item>
<p>The results of present examination may suggest that polymorphism of <italic>G196A BDNF</italic> gene does not result in a higher risk of addiction for the examined psychoactive substances.</p>
</list-item>
<list-item>
<p>Although the discussed genetic changes can influence the clinical course of addiction, they are not of crucial importance.</p>
</list-item>
</list>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112459203">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112459203">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Bree</surname>
<given-names>MBM</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Pickens</surname>
<given-names>RW</given-names>
</name>
</person-group>. <article-title>Genetic and environmental influences on drug use and abuse/dependence in male and female twins</article-title>. <source>Drug Alcohol Depend</source> <year>1998</year>; <volume>52</volume>: <fpage>231</fpage>–<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112459203">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samochowiec</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mordasewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arentowicz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Samochowiec</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Wplyw badań genetycznych na poznanie patogenezy uzależnień</article-title>. <source>Psychiatria</source> <year>2005</year>; <volume>2</volume>: <fpage>9</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112459203">
<label>3</label>
<citation citation-type="thesis">
<person-group person-group-type="author">
<name>
<surname>Biskupska</surname>
<given-names>J</given-names>
</name>
</person-group>. <source>Estimation of DRD2 and BDNF genes polymorphism genome and biochemical urine profile of addicted patients</source> <comment>(in Polish). PhD Dissertation</comment>, <publisher-name>Pomeranian University of Medicine</publisher-name>, <publisher-loc>Szczecin</publisher-loc>, <year>2009</year>.</citation>
</ref>
<ref id="bibr4-0960327112459203">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhl</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Naiman</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms</article-title>. <source>Am J Hum Genet</source> <year>2001</year>; <volume>69</volume>: <fpage>1290</fpage>–<lpage>1300</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112459203">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beuten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Quezada</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Significant association of BDNF haplotypes in European-American male smokers but not European-American female or African-American smokers</article-title>. <source>Am J Med Genet B Neuropsychiat Genet</source> <year>2005</year>; <volume>139B</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112459203">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leszczyńska-Rodziewicz</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Farmakogenetyka leków przeciw-psychotycz-nych</article-title>. <source>Psychiatria</source> <year>2004</year>; <volume>1</volume>(<issue>2</issue>): <fpage>81</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112459203">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsushita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyakawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Masaki</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Association study of brain-derived neurotrophic factor gene polymorphism and alcoholism</article-title>. <source>Alcohol Clin Exp Res</source> <year>2004</year>; <volume>28</volume>: <fpage>1609</fpage>–<lpage>1612</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112459203">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Brain-derived neurotrophic factor (val66met) genetic polymorphism is associated with substance abuse in males</article-title>. <source>Brain Res Mol Brain Res</source> <year>2005</year>; <volume>140</volume>
<issue>(1–2)</issue>: <fpage>86</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112459203">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>O’Hara</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Gorelick</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Newlin</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Vlahov</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic vulnerability to drug abuse. The D2 dopamine receptor TaqIB1 restriction fragment length polymorphism appears more frequently in polysubstance abusers</article-title>. <source>Arch Gen Psychiatry</source> <year>1992</year>; <volume>49</volume>: <fpage>723</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112459203">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gratacós</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gonzales</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Mercader</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>de Cid</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Urretavizcaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Estivill</surname>
<given-names>X</given-names>
</name>
</person-group>. <article-title>Brain-derived neurotrophic factor val66met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders and schizophrenia</article-title>. <source>Biol Psychiatry</source> <year>2007</year>; <volume>61</volume>: <fpage>911</fpage>–<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112459203">
<label>11</label>
<citation citation-type="thesis">
<person-group person-group-type="author">
<name>
<surname>Karlin Grażewicz</surname>
<given-names>K</given-names>
</name>
</person-group>. <source>Polymorphism of BDNF gene and tobacco smoking</source> <comment>(in Polish)</comment>. <comment>PhD Dissertation</comment>, <publisher-name>Pomeranian University of Medicine</publisher-name>, <publisher-loc>Szczecin</publisher-loc>, <year>2008</year>.</citation>
</ref>
<ref id="bibr12-0960327112459203">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sekine</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nada</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Association study between BDNF gen polymorphisms and methamphetamine abusers in Japan</article-title>. <source>Am J Med Genet Nueropsychiatr Genet</source> <year>2005</year>; <volume>132B</volume>: <fpage>70</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112459203">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lichtermann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Franke</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Pharmacogenomics and addiction to opiates</article-title>. <source>Eur J Pharmacol</source> <year>2000</year>; <volume>355</volume>: <fpage>R1</fpage>–<lpage>R3</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112459203">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreek</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bart</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lilly</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Laforge</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Pharmacogenetics of human molecular genetics of opiate and cocaine addictions and their treatments</article-title>. <source>Pharmacol Rev</source> <year>2005</year>; <volume>57</volume>: <fpage>1</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112459203">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanyukov</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Tarter</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Kirisci</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kirillova</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Maher</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>DB</given-names>
</name>
</person-group>. <article-title>Liability to substance use disorders: 1.Common mechanisms and manifestations</article-title>. <source>Neurosci Biobehav Rev</source> <year>2003</year>; <volume>27</volume>: <fpage>507</fpage>–<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112459203">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safranow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rzewuski</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bińczak Kuleta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Czyżycka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Skowronek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jakubowska</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>ADA2 allele of the adenosine deaminase gene may protect against coronary artery disease</article-title>. <source>Cardiology</source> <year>2007</year>; <volume>108</volume>: <fpage>275</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112459203">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomita Mitchell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muniappan</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Herrero Jimenez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zarbl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thilly</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Single nucleotide polymorphism spectra in newborns and centenarians: identification of genes coding for rise of mortal disease</article-title>. <source>Gene</source> <year>1998</year>; <volume>223</volume>: <fpage>381</fpage>–<lpage>391</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>